World Journal of Biology Pharmacy and Health Sciences
eISSN: 2582-5542
Cross Ref DOI: 10.30574/wjbphs
Journal homepage: https://wjbphs.com/

(REVIEW ARTICLE)

Diabetes-induced retinopathy: An updated review on risk factors, diagnosis, and management strategies

N. VISHVA [1,*], A. VASANTH [1], M. VISHNUPRIYA [1], R. RAJAPANDI [2] and S. GOPIKRISHNAN [3]

[1] *Doctor of Pharmacy, Arulmigu Kalasalingam College of Pharmacy, Viruthunagar, Tamilnadu, India - 626126.*
[2] *Department of Pharmaceutical Chemistry, Arulmigu Kalasalingam College of Pharmacy, Viruthunagar, Tamilnadu, India – 626126.*
[3] *Department of Pharmacology, Arulmigu Kalasalingam College of Pharmacy, Viruthunagar, Tamilnadu, India – 626126.*

World Journal of Biology Pharmacy and Health Sciences, 2023, 15(01), 217–220

Publication history: Received on 16 June 2023; revised on 25 July 2023; accepted on 28 July 2023

Article DOI: https://doi.org/10.30574/wjbphs.2023.15.1.0323

Abstract

Diabetes-induced retinopathy is a leading cause of visual impairment and blindness worldwide. This review provides an updated overview of the risk factors, diagnosis, and management strategies for diabetes-induced retinopathy. The pathogenesis of retinopathy in diabetes is multifactorial, involving both metabolic and vascular mechanisms. Several risk factors, including chronic hyperglycemia, hypertension, dyslipidemia, and duration of diabetes, contribute to the development and progression of retinopathy. Early detection and timely intervention are crucial for preventing vision loss and managing the disease effectively. Various diagnostic modalities, such as fundus photography, optical coherence tomography, and fluorescein angiography, play a pivotal role in the diagnosis and monitoring of retinopathy. Management strategies for diabetes-induced retinopathy encompass both medical and surgical interventions. Optimal glycemic control, blood pressure management, and lipid control are fundamental in preventing and slowing the progression of retinopathy. Additionally, novel therapeutic approaches, including anti-vascular endothelial growth factor (VEGF) agents, intravitreal steroids, and laser photocoagulation, are emerging as effective treatment options. This review aims to provide healthcare professionals with an updated understanding of the risk factors, diagnostic techniques, and management strategies for diabetes-induced retinopathy, ultimately promoting better patient care and visual outcomes.

Keywords: Diabetes; Retinopathy; Updated review; Risk factors; Diagnosis; Management strategies

1. Introduction

Diabetes-induced retinopathy is a common and potentially sight-threatening complication of diabetes mellitus [1]. It is characterized by progressive damage to the blood vessels of the retina, the light-sensitive tissue at the back of the eye [2]. The condition is primarily associated with prolonged hyperglycemia (high blood sugar levels) and is more prevalent in individuals with type 1 diabetes and type 2 diabetes [3]. Retinopathy develops gradually over time, and its severity can vary widely among individuals. Chronic hyperglycemia leads to microvascular changes, including the weakening, leakage, and proliferation of blood vessels in the retina. These changes can result in vision impairment and, in severe cases, blindness [4].

Diabetes-induced retinopathy is a multifactorial disease influenced by various risk factors, including the duration of diabetes, glycemic control, blood pressure levels, lipid abnormalities, genetic predisposition, obesity, and smoking [5]. Hypertension and dyslipidemia further contribute to the progression of retinopathy [6]. Early detection and timely

* Corresponding author: N. VISHVA

intervention are crucial in managing diabetes-induced retinopathy. Regular eye examinations, including dilated fundus examinations and specialized imaging tests, facilitate early diagnosis and monitoring of retinal changes [7].

2. Risk Factors Associated with Diabetes-Induced Retinopathy

Diabetes-induced retinopathy is influenced by various risk factors that contribute to its development and progression. Chronic hyperglycemia, a hallmark of diabetes, plays a central role in the pathogenesis of retinopathy [8]. Prolonged exposure to high blood glucose levels leads to microvascular damage in the retina, resulting in retinal ischemia and subsequent neovascularization [9]. Hypertension, another common comorbidity in diabetes, further exacerbates retinal vascular dysfunction and increases the likelihood of retinopathy [10]. Dyslipidemia, characterized by elevated triglycerides and LDL cholesterol, contributes to retinal microvascular damage and the progression of retinopathy [11]. Other factors, such as the duration of diabetes, genetic predisposition, obesity, smoking, and comorbidities like kidney disease and cardiovascular disease, further augment the risk of developing retinopathy in individuals with diabetes. Understanding and addressing these risk factors are crucial in preventing and managing diabetes-induced retinopathy. Comprehensive risk factor assessment, along with targeted interventions for glycemic control, blood pressure management, lipid control, and lifestyle modifications, are essential for preserving retinal health and minimizing the risk of vision loss in individuals with diabetes [12].

3. Diagnosis and Screening Approaches for Diabetes-Induced Retinopathy

Diagnosis and screening approaches play a vital role in the early detection, monitoring, and management of diabetes-induced retinopathy [13]. Timely identification of retinopathy is crucial for initiating appropriate interventions and preventing vision loss. Several diagnostic modalities are utilized in clinical practice to assess retinal health in individuals with diabetes.

Fundus photography is a widely used technique that captures detailed images of the retina, allowing for the identification of retinopathy-related changes, such as microaneurysms, hemorrhages, and exudates [14]. Optical coherence tomography (OCT) provides cross-sectional images of retinal layers, enabling the detection of macular edema and other structural abnormalities [15]. Fluorescein angiography involves the intravenous injection of a fluorescent dye to visualize retinal blood vessels and identify areas of abnormal perfusion and leakage [16].

Emerging diagnostic techniques, such as ultra-widefield imaging and OCT angiography, show promise in enhancing the detection and monitoring of retinopathy[17]. Ultra-widefield imaging provides a broader view of the retina, facilitating the identification of peripheral lesions. OCT angiography enables the visualization of retinal microvasculature without the need for contrast agents [18].

4. Management Strategies for Diabetes-Induced Retinopathy

Management strategies for diabetes-induced retinopathy encompass a comprehensive approach aimed at preventing or slowing the progression of retinal damage and preserving visual function [19]. Optimal glycemic control is fundamental in managing retinopathy [20].

In advanced stages of retinopathy, various therapeutic interventions are available. Laser photocoagulation has been the standard treatment for proliferative retinopathy [21], while intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents have revolutionized the management of diabetic macular edema [22], In some cases, vitrectomy may be necessary to address severe complications, such as vitreous hemorrhage or tractional retinal detachment [23].

Regular ophthalmologic examinations, including dilated fundus examinations and imaging studies such as optical coherence tomography (OCT) and fluorescein angiography, are essential for monitoring retinal health and determining the need for intervention [24].

5. Novel Therapeutic Approaches for Diabetes-Induced Retinopathy

Novel therapeutic approaches for diabetes-induced retinopathy are continuously being explored to enhance the management and treatment of this condition [25]. One promising area of research is the development of anti-vascular endothelial growth factor (VEGF) therapies. These agents work by inhibiting the action of VEGF, a protein that promotes abnormal blood vessel growth in the retina [26]. Anti-VEGF therapies have shown efficacy in treating diabetic macular edema and proliferative diabetic retinopathy [27].

Cell-based therapies, such as the use of mesenchymal stem cells or retinal progenitor cells, are also being investigated [28]. These cells have the potential to promote retinal repair, modulate inflammation, and improve retinal function. Other novel approaches include the exploration of neuroprotective agents, anti-inflammatory drugs, and gene therapies that aim to target specific genes involved in retinal damage [29].

6. Conclusion

Overall, this article serves as a valuable resource for the medical community, empowering them with the knowledge needed to make informed decisions and drive further advancements in the field of diabetes-induced retinopathy. By fostering ongoing research and collaboration, we can work towards a future where this debilitating complication can be effectively managed and potentially prevented, leading to improved eye health and well-being for diabetic patients worldwide.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Behl T, Kaur I, Kotwani A. Implication of oxidative stress in progression of diabetic retinopathy. Survey of ophthalmology. 2016 Mar 1, 61(2):187-96.

[2] Villarejo-Zori B, Jiménez-Loygorri JI, Zapata-Muñoz J, Bell K, Boya P. New insights into the role of autophagy in retinal and eye diseases. Molecular Aspects of Medicine. 2021 Dec 1, 82:101038.

[3] Clausen TD, Mathiesen ER, Hansen T, Pedersen O, Jensen DM, Lauenborg J, Damm P. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. Diabetes care. 2008 Feb 1, 31(2):340-6.

[4] Franjic S. In Shortly about Retinopathy. MAR Ophthalmology. 2021 Apr 13, 2(1).

[5] Satirapoj B. Nephropathy in diabetes. Diabetes: An Old Disease, a New Insight. 2013:107-22.

[6] Jeng CJ, Hsieh YT, Yang CM, Yang CH, Lin CL, Wang IJ. Diabetic retinopathy in patients with diabetic nephropathy: development and progression. PLoS One. 2016 Aug 26, 11(8):e0161897.

[7] Thompson IA, Durrani AK, Patel S. Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy. Eye. 2019 Apr, 33(4):648-52.

[8] Simo R, Simo-Servat O, Bogdanov P, Hernández C. Diabetic retinopathy: role of neurodegeneration and therapeutic perspectives. The Asia-Pacific Journal of Ophthalmology. 2022 Mar 1, 11(2):160-7.

[9] Aiello LP. The potential role of PKC β in diabetic retinopathy and macular edema. Survey of ophthalmology. 2002 Dec 1, 47:S263-9.

[10] Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. The journal of clinical hypertension. 2011 Apr, 13(4):244-51.

[11] Brown WV. Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection. The American journal of cardiology. 2008 Dec 22, 102(12):10L-3L.

[12] American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes care. 2010 Jan, 33(Suppl 1):S11.

[13] Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes care. 2003 Sep 1, 26(9):2653-64.

[14] Qureshi I, Ma J, Abbas Q. Diabetic retinopathy detection and stage classification in eye fundus images using active deep learning. Multimedia Tools and Applications. 2021 Mar, 80:11691-721.

[15] Srinivasan VJ, Wojtkowski M, Witkin AJ, Duker JS, Ko TH, Carvalho M, Schuman JS, Kowalczyk A, Fujimoto JG. High-definition and 3-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology. 2006 Nov 1, 113(11):2054-65.

[16] De Carlo TE, Romano A, Waheed NK, Duker JS. A review of optical coherence tomography angiography (OCTA). International journal of retina and vitreous. 2015 Dec, 1:1-5.

[17] Russell JF, Flynn Jr HW, Sridhar J, Townsend JH, Shi Y, Fan KC, Scott NL, Hinkle JW, Lyu C, Gregori G, Russell SR. Distribution of diabetic neovascularization on ultra-widefield fluorescein angiography and on simulated widefield OCT angiography. American journal of ophthalmology. 2019 Nov 1, 207:110-20.

[18] Or C, Sabrosa AS, Sorour O, Arya M, Waheed N. Use of OCTA, FA, and ultra-widefield imaging in quantifying retinal ischemia: a review. The Asia-Pacific Journal of Ophthalmology. 2018 Jan 1, 7(1):46-51.

[19] Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI insight. 2017 Jul 7, 2(14).

[20] Imran SA, Rabasa-Lhoret R, Ross S, Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Targets for glycemic control. Canadian journal of diabetes. 2013 Apr 1, 37:S31-4.

[21] Nagpal M, Marlecha S, Nagpal K. Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser. Retina. 2010 Mar 1, 30(3):452-8.

[22] Sugimoto M, Tsukitome H, Okamoto F, Oshika T, Ueda T, Niki M, Mitamura Y, Ishikawa H, Gomi F, Kitano S, Noma H. Clinical preferences and trends of anti-vascular endothelial growth factor treatments for diabetic macular edema in Japan. Journal of Diabetes Investigation. 2019 Mar, 10(2):475-83.

[23] Gonzales CR, Boshra J, Schwartz SD. 25-Gauge pars plicata vitrectomy for stage 4 and 5 retinopathy of prematurity. Retina. 2006 Sep 1, 26(7):S42-6.

[24] Wilkins JR, Puliafito CA, Hee MR, Duker JS, Reichel E, Coker JG, Schuman JS, Swanson EA, Fujimoto JG. Characterization of epiretinal membranes using optical coherence tomography. Ophthalmology. 1996 Dec 1, 103(12):2142-51.

[25] Usuelli V, La Rocca E. Novel therapeutic approaches for diabetic nephropathy and retinopathy. Pharmacological Research. 2015 Aug 1, 98:39-44.

[26] Chen Z, Morales JE, Avci N, Guerrero PA, Rao G, Seo JH, McCarty JH. The vascular endothelial cell-expressed prion protein doppel promotes angiogenesis and blood-brain barrier development. Development. 2020 Sep 15, 147(18):dev193094.

[27] Cheung N, Wong IY, Wong TY. Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications. Diabetes care. 2014 Apr 1, 37(4):900-5.

[28] Davey GC, Patil SB, O'Loughlin A, O'Brien T. Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus. Frontiers in endocrinology. 2014 Jun 6, 5:86.

[29] Simo R, Hernandez C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Progress in retinal and eye research. 2015 Sep 1, 48:160-80.